Additionally, genetic dysfunction of GPIbα as well as anti‐GPIbα antibody treatment reduces nonalcoholic steatohepatitis and subsequent hepatocellular carcinoma development [15]. Here, GP1BA is linked to metabolic dysfunction-associated steatohepatitis.